Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2017)
19 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 27, 2017
Slide 1: Phylogica: Pivot to Platform
For personal use only Phylogica: Pivot to Platform AGM Presentation By CEO Stephanie Unwin November 2017
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: We must pivot from developing drugs to commercialising the platform
We must pivot from developing drugs to For personal use only commercialising the platform Value proposition: Enhance existing drugs to address a large and growing $250Bn USD market 1 Bring drugs 2 3 Enhance Reduce to the right properties of discovery place drugs (e.g., cycle time (i.e., to improve (
Slide 4: Our advantage is in using our assets as a platform to solve Pharma problems
Our advantage is in using our assets as a platform to solve Pharma problems For personal use only Phylogica has unique, valuable assets … … for a huge potential market • Complex, rich Phylomer library –target • Unmet need – undruggable $250Bn identification or drug discovery growth market, intracell
Slide 5: Value to Pharma shown by validating diverse sets of cargoes and cell types
Value to Pharma shown by validating diverse sets of cargoes and cell types For personal use only FPP01 validation matrix Oligo- Expand to Peptides Scaffolds Enzymes Antibodies nucleotide new cargoes Breast Phylogica is validating tumour FPP’s across a matrix of Blood cancer possible cargoes and Bone
Slide 6: 2018: PYC funded to validate cargoes/targets increasing Pharma interest
2018: PYC funded to validate cargoes/ targets increasing Pharma interest in partnering for drug discovery For personal use only b-actin Cre 6
Slide 7: Phylogica shortens Pharma discovery phase
Phylogica shortens Pharma discovery phase For personal use only Typical drug PRECLINICAL CLINICAL DRUG DISCOVERY FDA APPROVAL discovery process (animal testing) (human trials) 5 years 1.5 years 6 years 1-2 years Typical Timelines Determination Drug safety Drug safety & Regulatory of a suitable & eff
Slide 8: In the platform landscape, PYC uses its technology for the undruggable
In the platform landscape, PYC uses its technology for the undruggable For personal use only Value Drugging the undruggable Pharmacokinetic Therapeutic discovery technology Application Diverse Matrix of targets and cargoes targets/ Dendrimer platforms across Protein, mAb, Cas9 cargoes modalities Pep
Slide 9: BIO: Customer feedback
BIO: Customer feedback For personal use only Lots of interest from target … who clearly see the need for customers… our platform technology “You’ve come a ” primary long way since therapeutic isn’t we last saw you” working …need a back up plan” “we need delivery to the cytosol” “We are facing ”Inter
Slide 10: PYC – the Platform: Phylogica is laser focused on 3 goals
To achieve PYC – the Platform: Phylogica is laser focused on 3 goals Outcome: For personal use only Further • More in vivo functional validation A validated, 1 prove the sought after • Improve our FPPs value of our platform • Enrich and validate our library platform that helps Pharma customers Trans
Slide 11: Thank you
For personal use only Thank you For more information contact Stephanie Unwin at stephanieu@phylogica.com
Slide 12: Significant constraints in existing drug discovery approaches
Significant constraints in existing drug discovery approaches For personal use only The Our problem? Phylomer solution? CPP Biologics - Antibodies - Scaffolds Drug discovery growth - rProteins We can bring stagnating as biologics biologics into the currently limited to cell, unlocking the extracellu
Slide 13: Harnessing the Microbiome for new Phylomer libraries
Harnessing the Microbiome for new Phylomer libraries For personal use only Current Phylomer libraries (size indicates number of genomes) Future Phylomer libraries Hug, Laura A et al. 2016. “A New View of the Tree of Life.” Nature Microbiology 1(5): 1-6 Board meeting – Science update 2
Slide 14: PYC has shown conclusively that FPPs work in animal models
PYC has shown conclusively that FPPs work in animal models For personal use only Inhibition of tumor growth in mouse cancer model Restoring dystrophin levels by FPP mediated delivery of DMD PMO Treated mice DMD oligo FPP1-DMD oligo Leg Diaphragm Heart Collaborator: Pilar Blancafort, Harry Perkins In
Slide 15: FPP1 has been significantly improved upon, and new variants are being validated in vitro
FPP1 has been significantly improved upon, and new variants are being validated in vitro For personal use only Flow cytometry N=2 Phylogica’s FPP FPP 1 improvement Negative Control FPP 2 program through rational design has Confocal demonstrated the microscopy ability to enhance potency with no incre
Slide 16: Into 2018, PYC is validating a comprehensive matrix of FPPs
Into 2018, PYC is validating a comprehensive matrix of FPPs - delivery of cargoes into different cell types For personal use only b-actin Cre 5
Slide 17: In progress validation - FPP peptide vaccine retards tumor growth
In progress validation - FPP peptide vaccine retards tumor growth For personal use only Our FPP peptide vaccine • Subcutaneous B16 approach: melanoma model engineered to express • Primes tumor specific CD8+ glycoprotein B (gB) from T-cells Herpes Simplex Virus • FPP containing peptide vaccine retard
Slide 18: Partnering strategy - Genentech work continues to be successful
Partnering strategy - Genentech work continues to be successful For personal use only • Isolating Phylomers that can help kill gram-negative bacteria (multi-drug resistant “super bugs”) • Evaluation period end of CY 2019 gram-positive gram-negative Antibiotic ✔ ✗ Phylomer ✗ ✗ Phylomer-Antibiotic ✔ ✔
Slide 19: Building on the success of the past, turning towards the future of FPPs
Building on the success of the past, turning towards the future of FPPs For personal use only New technologies Building Therapeutics Logically HTP automation to rapidly discover the best molecules in our new libraries Identify FPPs that work well in different cell types and tissues Working with so